Kenneth Widder

Nov 19, 2014

Kenneth Widder has joined Quidel’s board, expanding the company’s board to eight members. Widder has more than 30 years of experience with biomedical companies and has been a general partner with Latterell Venture Partners since 2007. He also serves on the board of Evoke Pharma, Mertiage Pharma, and Naurex.

Breaking News

T2 Biosystems Q2 Revenues More Than Double, Beat Estimates
Quidel Q2 Revenues Dip 12 Percent; Misses on Revenues and EPS Estimates
Natera Q2 Revenues Grow 64 Percent
Guardant Health Q2 Revenues Grow 39 Percent
Fluidigm Q2 Revenues Grow 19 Percent
Illumina Q2 Revenues Jump 78 Percent

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.